Advanced Microbiome Therapeutics : the Potential of Engineered Microbes
Metabolic diseases like obesity and type 2 diabetes have long presented significant treatment challenges. Traditional peptide-based drugs, while effective, often struggle with issues like poor bioavailability and the need for injection, which can hamper patient adherence.
In this review (https://lnkd.in/emTydQaB) authors explore the concept of Advanced Microbiome Therapeutics (AMTs), therapeutics that are designed to overcome these limitations. These engineered microbes enhance peptide stability and bioavailability, making oral delivery feasible and effective.
Preclinical studies have shown promising results, particularly in animal models, demonstrating significant potential in managing conditions like obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD).
- AMTs enable in situ production of therapeutic peptides, addressing the challenges of short-lived and poorly bioavailable peptide-based drugs.
- Studies have shown that AMTs can significantly reduce weight gain, improve glucose tolerance, and enhance liver health in animal models.
- The potential for AMTs to be tailored to individual patient needs offers a new horizon for personalized medicine in a wider range of metabolic disease treatment including cancers.
However, challenges remain in optimizing peptide expression, colonization control, and ensuring safety and stability. Despite these hurdles, AMTs hold immense promise for revolutionizing the treatment landscape of metabolic diseases.
#MicrobiomeTherapeutics #SyntheticBiology #Biotechnology #PersonalizedMedicine
Thanks for sharing!